valuation of prophylactic effect of oral Transamine on severity of bleeding

Evaluation of prophylactic effect of oral Transamine on severity of bleeding in children with congenital platelet function disorders

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200812048378N1

Enrollment

Registered

2020-08-19

Start date

2020-08-22

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Von Wilbirand-Bairnald Solaire-Glynsman-Hemophilia. https://icd.who.int/browse10/2019/en#/D69.1

Interventions

Intervention 1: " the intervention group"Single dose transamin company made in 25 mg/kg per day will be taken as oral pill at 8 pm for 3 months before intervention, at the end of the first month, at

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Approved hereditary platelet dysfunction 2. Age over 2 and under 18 years 3. Lack of sensitivity to transamines 4. No history of thromboembolism

Exclusion criteria

Exclusion criteria: Dissatisfaction to continue the study Death of patients for any reason during the examination period Lack of regular visits to the clinic for follow-up treatment

Design outcomes

Primary

Measure	Time frame
Bleeding in children with hereditary dysfunction. Timepoint: 30, 60 and 90 days after starting the drug. Method of measurement: Intensity and frequency of hereditary bleeding according to ISTH bleeding score before intervention, end of one month, end of two months and end of three months after intervention.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fateme Mir

Mashhad University of Medical Sciences

mirf4334@gmail.com+98 51 3879 8014

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026